Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Immunome and keeping the price target at $40.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors, chiefly the strong late-stage data for varegacestat in desmoid tumors and the nearing NDA filing. The Phase 3 RINGSIDE results showed a marked benefit in progression-free survival, high response rates, and deep tumor shrinkage, supporting best-in-class potential in a setting with few effective systemic options and a meaningful U.S. commercial opportunity.

At the same time, Maldonado emphasizes Immunome’s expanding next-generation ADC platform and broader pipeline as key long-term value drivers. The lead ROR1-directed ADC IM-1021 is already in Phase 1 with early responses, while multiple additional HC74-based ADCs and a FAP-targeted radioligand therapy are advancing toward the clinic, illustrating a differentiated oncology platform with both near-term catalysts and durable growth prospects.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $40.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMNM in relation to earlier this year.